UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
ArQule, Inc.
(Name of Issuer)
Common Stock, $.001 par value
(Title of Class of Securities)
04269E107
(CUSIP Number)
Margaret M. Foran
Senior Vice President, Associate General Counsel
and Corporate Secretary
Pfizer Inc. 235 East 42nd Street
New York, New York 10017
( 212)-733-4802
(Name, Address and Telephone Number of Person Authorized to Receive
Notices and Communications)
December 31, 2005
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition that is the subject of this Schedule 13D, and is
filing this schedule because of Sec. 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g),
check the following box. __
The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).
CUSIP No. 04269E107.................................
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only)
Pfizer Inc.; 13-5315170
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
(b) X
3. SEC Use Only ........................................................................................
4. Source of Funds (See Instructions) ......WC..................................................
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items
2(d) or 2(e)
6. Citizenship or Place of Organization - Delaware
Number of Shares Beneficially Owned by Each Reporting Person With:
7. Sole Voting Power.. 0.............
8. Shared Voting Power
9. Sole Dispositive Power 0
10. Shared Dispositive Power ........................................................................................
11. Aggregate Amount Beneficially Owned by Each Reporting Person. 3,273,679.............
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See
Instructions) ...X
13. Percent of Class Represented by Amount in Row (11) 9.3%
14. Type of Reporting Person (See Instructions) - CO .
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
ArQule, Inc.
(Name of Issuer)
Common Stock, $.001 par value
(Title of Class of Securities)
04269E107
(CUSIP Number)
Margaret M. Foran
Senior Vice President, Associate General Counsel
and Corporate Secretary
Pfizer Inc. 235 East 42nd Street
New York, New York 10017
( 212)-733-4802
(Name, Address and Telephone Number of Person Authorized to Receive
Notices and Communications)
December 31, 2005
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition that is the subject of this Schedule 13D, and is
filing this schedule because of Sec. 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g),
check the following box. __
The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).
CUSIP No. 04269E107.................................
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only)
Pfizer Holdings Europe (no IRS Identification No.)
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
(b)
3. SEC Use Only ........................................................................................
4. Source of Funds (See Instructions) ......WC..................................................
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items
2(d) or 2(e)
6. Citizenship or Place of Organization - Republic of Ireland
Number of Shares Beneficially Owned by Each Reporting Person With:
7. Sole Voting Power.. 3,273,679.............
8. Shared Voting Power
9. Sole Dispositive Power 3,273,679
10. Shared Dispositive Power ........................................................................................